Federal Register of Legislation - Australian Government

Primary content

PB 16 of 2012 Determinations/Health as made
This instrument removes from its therapeutic group, effective 1 April 2012, each listed drug which has at least one listed brand to which section 99ADH will apply on that date. Section 99ADH deals with price disclosure price reductions. It also removes the therapeutic groups, CCB group (the Dihydropyridine calcium-channel blocker group); and Statins group (the HMG Co-A reductase inhibitor group)as subsection 84AG(5) of the Act provides that a therapeutic group must contain at least one listed drug.
Administered by: Health
Registered 26 Mar 2012
Tabling HistoryDate
Tabled HR08-May-2012
Tabled Senate10-May-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2012 (No. 1)

Instrument number PB 16 of 2012

National Health Act 1953

I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this determination under subsection 84AG(1) of the National Health Act 1953.

Dated                   20 March    2012

 

 

 

 

 

 

 

 

 

ADRIANA PLATONA

 

Assistant Secretary

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health and Ageing

 


1              Name of Determination

       (1)     This Determination is the National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2012 (No. 1).

       (2)     This Determination may also be cited as PB 16 of 2012.

2              Commencement

                This Determination commences on 1 April 2012.

 

 

3              Amendments to PB 1 of 2010

Schedule 1 amends the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010 (PB 1 of 2010).


Schedule 1             Amendments

 

[1]      Section 4, omit definition of CCB group

           

[2]      Section 4, omit definition of Statins group

      

[3]      Schedule 1, Part 1

          omit:

         

1

Captopril

2

Enalapril

 

 

[4]       Schedule 1, Part 1

           omit:

 

4

Lisinopril

5

Perindopril

6

Quinapril

7

Ramipril

8

Trandolapril

 

 

[5]       Omit entry for Schedule 1, Part 3

 

 

[6]       Schedule 1, Part 4

           omit:

 

2

Famotidine

 

 

[7]       Schedule 1, Part 5

            omit:

 

2

Lansoprazole

3

Omeprazole

4

Pantoprazole

            

 

[8]       Omit entry for Schedule 1, Part 6

 

 

Note

1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.frli.gov.au.